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noted in 14/38 (37%); IFA-IgG-SFG in 7, IFA-IgG-OT in 3 and for
both in 4. Of the 14; titre of 1:128 in 2, 1:256 in 4, 1:512 in 5, >1:
1024 in 3 and 8/14 (57%) were SLE, 3/14 (21.4%%) were ITP, 2/14
(14.3%) were AIHA, 1/14 (7.1%) were polymyositis and none were
thyroiditis. 8/14 had received anti-rickettsial antibiotics during
the early stages of illness based on the clinical presentation and
high IFA-IgG titres.
Conclusion: Therewas a signiﬁcant reactivity of Rickettsial dis-
ease IFA-IgG assay in auto-immune diseases. Further studies are
needed in order to ascertainwhether this is due to recent rickettsial
infections, false positive cross reactivity of autoimmune antibod-
ies with rickettsial antigens or with cell culture nuclear antigens.
We did not carry out IFA-IgM due to non-availability and non-
affordability.
http://dx.doi.org/10.1016/j.ijid.2016.02.175
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Background: Rickettsia sp. causes rickettsioses, which despite
being among the oldest known arthropod-borne diseases, are
now recognized as important emerging vector-borne infections of
humans worldwide. In Kenya, the prevalence of these diseases is
poorly understood leading to far-reaching public health implica-
tions such as the unexplained fevers problem, some of which are
caused by different spotted fever group (SFG) rickettsiae.
Methods & Materials: We used a multi-genic approach to
identify rickettsia from 4,324 questing ticks (209 adult ticks, 586
nymphs and3,502 larvae) processed into 270pools of varying sizes,
dependingon species and life-cycle stages.Weﬁrst performedPCR-
high resolution melting point (HRM) based on Rickettsia 16S rRNA
gene followed by sequencing of unique melt proﬁles. Sequences
were identiﬁed by comparisons using BLASTn method. Thereafter,
we re-ampliﬁed and sequenced citrate synthase (gltA) and outer
membrane protein B (ompB) genes, as well as the highly variable
rpmE-tRNAfMet intergenic spacer for samples with unique rick-
ettsial 16S amplicon HRM proﬁles.
Results: We report the molecular detection of Rickettsia africae
in Amblyomma eburneum ticks and novel Rickettsia-like species in
Rhipicephalus maculatus ticks for the ﬁrst time. We detected R.
africae DNA with 99-100% identity for all the ampliﬁed gene loci
while identities of two Rickettsia-like species could not be ascer-
tained due to identical similarities associated with more than one
Rickettsia species across the ampliﬁed gene loci. Sequence analysis
of gltA gene for these two Rickettsia-like species showed 98% iden-
tity across severalRickettsia sp.The ompBgene couldnot amplify for
one of the species which also had 97% identity with R. bellii based
on the rpmE-tRNAfMet intergenic spacer sequence.
Conclusion: The detection of R. africae, an important emerging
pathogen in Sub-Saharan Africa as well as novel Rickettsia sp. with
unknown pathogenicity in this study represent signiﬁcant ﬁndings
that may explain the occurrence of some unidentiﬁed febrile ill-
nesses contributing to human morbidity. Additionally, our study
outlines the indispensable role of molecular methods in routine
surveillance to monitor both known and novel pathogens likely to
be emerging threats.
http://dx.doi.org/10.1016/j.ijid.2016.02.176
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Background: Kala-azar elimination initiative launched in 2005
in South Asia aims to reach the target by 2017. Early diagnosis and
effective treatment is one of the key strategies for control along
with integrated vector management. Single dose Ambisome (SDA)
and combination regimens are the recommended treatments in
South Asia. Our objective was to assess feasibility of using these
treatments within the public health facilities and document 12
month outcome.
Methods & Materials: This was an open label, prospective,
non-randomised, non-comparative, multicentric trial conducted at
public health facilities. The study was conducted from Aug 2012
to Sep 2015 at 02 districts (Vaishali and Saran) in Bihar and at
kala-azar referral hospital (Rajendra Memorial Research Institute
of Medical Sciences) in Patna.
In Vaishali district, patients were treated with SDA (10mg/kg)
at the District hospital and A+M (single dose Ambisome 5mg/kg +
miltefosine 7 days) at 5 primary healthcare centres (PHC). In Saran
District, M+P (Miltefosine and Paromomycin) for 10 days at district
hospital and 3 PHC.
All patientswere followedup to document outcomeat 6months
and cohort of them were followed for 12 months.
Results: 1761 patients were treated in the study, achieved cure
rate of > 99% at initial outcome (Day 10) in each treatment arm.
The cure rates at 6 months were 90.9% (95% CI 89.0-92.8) for SDA
(n=892), 88.8% (CI 85.5-92.1) for A+M (n=357) and 97.0% (CI 95.6-
98.5) for M+P arm (n=512). During 12 month FU (n=1386) there
were 11 additional relapses, 2 in SDA (n=706) and 6 in A+M (n=294)
and 3 inM+P (n=386). 12 patients developed PKDL inM+P arm, 1 in
A+M arm and 2 in SDA. Five SAE occurred in SDA arm, 2 considered
related and 3 non-related to Ambisome, all of them resolved.
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Conclusion: The new treatment regimens showed excellent
outcome and safety proﬁle to be used within the programme set-
tings. On the basis of these results, Indian national program have
revised the treatment policy in Sep 2014 where SDA has been rec-
ommended as the 1st option and M+P as the 2nd option. Extension
of FU beyond the standard 6 months yielded additional relapses
and PKDL cases.
http://dx.doi.org/10.1016/j.ijid.2016.02.177
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Background: Post-kala-azar dermal leishmaniasis (PKDL), a
cutaneous sequela of visceral leishmaniasis (VL), develops in
approximately 10% of treated VL patients in the Indian subconti-
nent and may act as a reservoir of disease. Current evidence for
treatment is limited; only long and toxic treatments currently exist
for a condition that is more a public health rather than an individ-
ual health problem. We describe the characteristics and outcome
of PKDL treated with liposomal amphotericin B (AmBisome®) in
MSF-supported facilities in India and Bangladesh.
Methods & Materials: We administered intravenous liposomal
amphotericin B 30 mg/kg body weight in 6 divided doses over 3
weeks on an ambulatory basis to patients with PKDL. To assess the
treatment response, trained physicians regularly scored the sever-
ity of lesions and took medical photographs at baseline and during
follow-up visits. The main end-points were safety of treatment,
with an emphasis on development of hypokalaemia, and efﬁcacy
at 12 months’ follow-up. Following safety concerns in Bangladesh,
we introduced a lower dose of 15mg/kg, given in 5 doses of 3mg/kg
over 3 weeks.
Results: 223 patients initiated treatmentwith the 30mg/kg reg-
imen, 110 in Bangladesh and 113 in India. In India, of 72 patients
who completed 12 months’ follow-up, 59 (82.2%) cases showed
substantial or compete cure, with excellent tolerance and safety.
In Bangladesh, of 88 patients who completed 12 months’ follow-
up, 70 (79.5%) showed substantial or complete cure; however,
6.5% developed severe hypokalaemia. No patients in either group
developed rhabdomyolysis or further sequelae. In Bangladesh, 278
patients were subsequently treated with the 15mg/kg regimen;
12-month follow-up results are available for 167. Of these, 147
(83%) showed substantial or complete cure. The safety proﬁle was
excellent with no severe hypokalaemia. We expect all results to be
available by March.
Conclusion: Short-course liposomal amphotericin B treatment
regimens for PKDL appeared to be effective and may be considered
as an option for the treatment of PKDL patients in India when bio-
chemical monitoring is available. However, levels of hypokalaemia
seen in Bangladeshi patients meant that a lower dosage regimen is
necessary, which appears to be safe and effective.
http://dx.doi.org/10.1016/j.ijid.2016.02.178
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Background: Leishmania (L.) donovani, a species of the L. dono-
vani complex, causes fatal visceral leishmaniasis (VL) disease in the
Indian Subcontinent, parts of Asia and a large part of Africa. Genetic
variations in Leishmania cause heterogeneity, spread of virulent
strains, resistance to chemotherapeutics and exploitation of differ-
ent hosts and vectors. Previously, L. donovani strains in the Indian
subcontinent were detected genetically homogeneous by MLMT.
Later study using genome-wide single nucleotide polymorphism
(SNP) markers showed that genetic variation existed in L. donovani
strains isolated from Nepal and India. We aimed to reveal intra-
species genetic variation between strains of L. donovani derived
from Bangladesh.
Methods & Materials: Twenty two newly isolated L. dono-
vani strains from VL cases were investigated in a cross sectional
study by MLST of seven functionally independent housekeeping
genes located in different chromosomes. Target loci were rhom-
boid like serine protease, fatty acid/sphingolipid -4 desaturase,
serine/threonine-protein kinase, 5’ A2rel-related gene, ubiquitin-
activating enzyme e1, mannosyltransferase and splicing factor
3B subunit1 gene. Sequences of respective genes of L. donovani
retrieved from GenBank and that obtained after sequencing of
reference strains of L. donovani and L. infantum were used for com-
parison.
Results: Unambiguous sites of SNPs were detected in analysed
sequences across all loci. The 5’ a2rel-related locus was the most
diverge region with 26 SNPs, followed by mannosyltransferase
with 10, splicing factor 3B subunit1 with 6, ubiquitin-activating
enzyme e1 with 5, rhomboid like serine protease with 4; fatty
acid/sphingolipid -4 desaturase and serine/threonine-protein
kinase possessed 1 SNPeach. Two large closely related clusters (one
contained 10 and the other 7 isolates) and ﬁve separate individual
groups among 22 Bangladeshi isolates were revealed by phylo-
genetic analysis showing the presence of 7 genotypes among L.
donovani strains in the country.
Conclusion: The study illustrates that intra-species genetic
diversity between strains of L. donovani does exist in Bangladesh.
A combination of sequencing of 5’ a2rel-related gene and manno-
syltransferase gene are sufﬁcient to differentiate strains of the L.
donovani. The MLST can be a future tool to determine intra- and
inter-species genetic variation of Leishmania.
http://dx.doi.org/10.1016/j.ijid.2016.02.179
